5-Amino-1MQ vs PT-141 (Bremelanotide)
5-Amino-1MQ and PT-141 (Bremelanotide) are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: 5-Amino-1MQ is small-molecule nnmt inhibitor (methylquinolinium salt) — not a peptide, while PT-141 (Bremelanotide) is cyclic heptapeptide, melanocortin receptor agonist — different molecular classes with different handling consequences; their leading degradation routes differ (microbial growth in non-preserved diluent for 5-Amino-1MQ, tryptophan photo-oxidation for PT-141 (Bremelanotide)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
5-Amino-1MQ — origin
5-Amino-1MQ is a small quinolinium molecule characterised as a first-in-class inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme studied at the intersection of adipocyte metabolism and the cellular NAD+/methylation pool. It is not an amino-acid chain, which is why it sits apart from every peptide in this catalogue.
PT-141 (Bremelanotide) — origin
PT-141 is a metabolite of Melanotan II, and its history is an unusually direct case of a side effect becoming the research programme. Melanotan II was developed as a synthetic α-MSH analogue for pigmentation research; an unanticipated effect observed during that work redirected attention to the metabolite, which was then developed separately as bremelanotide.
5-Amino-1MQ research themes
The defining mechanism — preclinical work has examined how blocking NNMT shifts methylation flux and NAD+ salvage in metabolic tissue models.
Studied in fat-cell models for effects on cellular energy handling and lipid metabolism.
Because NNMT consumes a methyl group tied to the NAD+ precursor pool, it is studied alongside the wider NAD+ research field.
PT-141 (Bremelanotide) research themes
Acts at melanocortin receptors, with MC3R and MC4R the subtypes of research interest.
Distinguished in the literature by acting centrally, unlike vascular-mechanism compounds in adjacent research areas.
Its origin as a metabolite of a pigmentation-research compound is central to understanding its development history.
The lactam bridge restricts conformational freedom, a common strategy for improving receptor selectivity.
5-Amino-1MQ handling
- Let the sealed vial reach room temperature before opening so moisture does not condense onto the powder.
- For cell-based assays, prepare a concentrated DMSO stock and dilute into aqueous buffer rather than dissolving directly at high concentration in medium.
- Label aliquots with reconstitution date and diluent.
PT-141 (Bremelanotide) handling
- Protect from light at all stages.
- Standard gentle reconstitution; the constrained ring is not agitation-sensitive in the way flexible long chains are.
- Store refrigerated and aliquot rather than repeatedly sampling one vial.
Both third-party tested
Every Popular Peptides batch of 5-Amino-1MQ and PT-141 (Bremelanotide) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
5-Amino-1MQ reference
Related comparisons
5-Amino-1MQ and PT-141 (Bremelanotide) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.